Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Warnex Reports Year End 2013 Results

LAVAL, QUEBEC--(Marketwired - April 24, 2014) - Warnex Inc. (TSX VENTURE:WNX.H) ("Warnex" or the "Company") announced today financial results for the year ended December 31, 2013.

Warnex sold its Bioanalytical Services division on December 10, 2012, which represented its last operating business unit. On December 2, 2013, the Company terminated its long-term operating lease for its Laval, Quebec facilities and sold one of its subsidiaries. "These transactions have allowed Warnex to eliminate all significant future financial commitments and to aggressively manage its operating expenses," remarked Michael Singer, Chairman of Warnex. "They have also provided the Company with the flexibility required in order to explore more optimally its strategic alternatives. In this regard, discussions with external parties continue to advance and the Company expects to announce the outcome of this process in the near term." 

Financial results

Consolidated revenue for the twelve-month period ended December 31, 2013, amounted to $nil compared to $9.0 million in 2012. The Company did not generate any sales, nor related cost of goods sold, in the year ended December 31, 2013, as a result of the sale of all of its operating divisions in 2012.

Net loss for twelve-month period amounted to $2.0 million or $0.07 per share compared to net earnings of $1.0 million or $0.04 per share for the same period in 2012.

Selling expenses amounted to $nil for the twelve-month period ended December 31, 2013, compared to $0.3 million for the twelve-month period ended December 31, 2012.

General and administrative expenses amounted to $1.1 million for the twelve-month period ended December 31, 2013 compared to $4.0 million for the same period in 2012.

Research and development tax credits amounted to $81,267 for the twelve-month period ended December 31, 2013 as a result of the reversal of prior period provisions following assessments by the taxation authorities ($139,998 in the year ended December 31, 2012).

Financial revenues amounted to $3,832 in the twelve-month period ended December 31, 2013 compared to financial expenses of $651,493 in the twelve-month period ended December 31, 2012. This decrease is due to the repayment in full of the Company's debts in 2012.

The Company ended fiscal 2013 with cash, cash equivalents and short-term investments of $2.1 million and working capital of $2.7 million, compared to $2.7 million in cash and a working capital of $4.1 million as at December 31, 2012.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For further information identifying known risks and uncertainties, relating to financial resources, liquidity risk, volatility of share price and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent annual Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Neither NEX nor its Regulation Services Provider (as that term is defined in policies of the NEX) accepts responsibility for the adequacy or accuracy of this release.

Financial statements to follow.

Consolidated Statements of Financial Position

  December 31
2013
$
  December 31
2012
$
 
Assets        
Current assets        
Cash and cash equivalents 218,299   2,742,114  
Short-term investments 1,900,000   -  
Trade and other receivables 782,073   1,804,421  
Prepaid expenses 55,483   70,779  
  2,955,855   4,617,314  
         
Non-current assets        
Amount receivable held in trust -   600,000  
  2,955,855   5,217,314  
         
Liabilities        
Current liabilities        
Trade and other payables 169,731   457,317  
Provisions 80,000   90,930  
  249,731   548,247  
         
Shareholders' equity        
Capital stock 41,706,049   41,706,049  
Other reserves 2,803,559   2,803,559  
Deficit (41,803,484 ) (39,840,541 )
  2,706,124   4,669,067  
  2,955,855   5,217,314  

Consolidated Statements of Changes in Shareholders' Equity

    Other reserves        
  Capital
stock
$
Equity components of debentures
$
Share-based compensation
$
Other
$
Total other reserves
$
Deficit
$
  Total
$
 
Balance, December 31, 2012 41,706,049 1,734,404 1,028,149 41,006 2,803,559 (39,840,541 ) 4,669,067  
Net and comprehensive loss - - - - - (1,962,943 ) (1,962,943 )
Balance, December 31, 2013 41,706,049 1,734,404 1,028,149 41,006 2,803,559 (41,803,484 ) 2,706,124  
                   
                   
Balance, December 31, 2011 40,981,049 1,734,404 1,028,149 41,006 2,803,559 (40,863,719 ) 2,920,889  
Issuance of common shares 725,000 - - - - -   725,000  
Net earnings and comprehensive income - - - - - 1,023,178   1,023,178  
Balance, December 31, 2012 41,706,049 1,734,404 1,028,149 41,006 2,803,559 (39,840,541 ) 4,669,067  

Consolidated Statements of Operations and Comprehensive Income

For the years ended December 31 2013
$
  2012
$
 
Revenue -   8,964,219  
Cost of goods sold -   7,049,073  
Gross margin -   1,915,146  
         
Operating expenses        
  Selling -   266,567  
  General and administrative 1,123,042   3,986,584  
  Finance (3,832 ) 651,493  
  Research and development tax credits (81,267 ) (139,998 )
  1,037,943   4,764,646  
         
Loss before under noted items and income taxes (1,037,943 ) (2,849,500 )
         
Gain on disposal of assets 50,001   4,261,178  
Lease termination (975,001 ) -  
Impairment of assets -   (388,500 )
         
Earnings (loss) before income taxes (1,962,943 ) 1,023,178  
Deferred income taxes -   -  
Net earnings (loss) and comprehensive income (1,962,943 ) 1,023,178  
         
Basic earnings (loss) per share ($0.07 ) $0.04  
Diluted earnings (loss) per share ($0.07 ) $0.04  
Weighted average number of shares outstanding 28,323,884   25,958,190  
Weighted average number of diluted shares outstanding 28,323,884   27,891,802  

Consolidated Statements of Cash Flow

For the years ended December 31 2013
$
  2012
$
 
Operations        
Net earnings (loss) (1,962,943 ) 1,023,178  
Items not affecting cash:        
Depreciation of property, plant and equipment -   707,352  
Amortization of intangibles -   32,117  
Impairment of assets -   388,500  
Gain on disposal of assets -   (4,261,178 )
  (1,962,943 ) (2,110,031 )
Net change in non-cash working capital items 1,339,128   (773,352 )
Net cash used in operations (623,815 ) (2,883,383 )
         
Investing activities        
Acquisition of property, plant and equipment -   (85,181 )
Proceeds of disposal of property, plant and equipment -   6,060,205  
Proceeds of disposal of intangibles -   58,477  
Acquisition of short-term investments (3,000,000 ) -  
Maturity and disposal of short-term investments 1,100,000   -  
Net cash provided by (used in) investing activities (1,900,000 ) 6,033,501  
         
Financing activities        
Decrease in bank loan -   (740,000 )
Repayment of long term debt -   (42,840 )
Repayment of debentures -   (910,400 )
Net cash used in financing activities -   (1,693,240 )
         
Increase (decrease) in cash and cash equivalents (2,523,815 ) 1,456,878  
Cash and cash equivalents, beginning of year 2,742,114   1,285,236  
Cash and cash equivalents, end of year 218,299   2,742,114  

Michael Singer
Chairman of the Board of Directors
Warnex Inc.
(514) 940-3600
info@warnex.ca

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today